BiotechTube
Aplex Bio

Aplex Bio

Stockholm, Sweden· Est.
aplex.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.8M

Overview

Aplex Bio is pioneering Hyperplex PCR (hpPCR), a quantitative endpoint PCR technology that combines padlock probes, rolling circle amplification (RCA), and proprietary Nanopixels™ to achieve unprecedented multiplexing (100+ targets/well), ultra-sensitivity (1 copy/reaction), and single-nucleotide specificity. The platform is designed to integrate seamlessly into standard lab workflows using existing equipment, offering an alternative to the high cost and complexity of NGS and the limited multiplexing of qPCR/dPCR. The company, based in Stockholm, is in the commercial stage for its assay kits, targeting the research tools and molecular diagnostics markets with a focus on applications requiring high-plex, precise genetic analysis.

Genetics & Genomics

Technology Platform

Hyperplex PCR (hpPCR): An endpoint quantitative PCR technology combining padlock probes for single-nucleotide specificity, rolling circle amplification (RCA) for signal amplification and molecular counting, and proprietary Nanopixels™ fluorescent nanoprobes enabling detection of 100+ targets in a single well using standard fluorescence readers.

Funding History

1
Total raised:$1.8M
Seed$1.8M

Opportunities

The primary opportunity is to capture market share in the large PCR and targeted analysis markets by offering a superior alternative that combines the high-plex and specificity of NGS with the speed, cost, and workflow simplicity of PCR.
The emphasis on compatibility with existing lab equipment creates a low barrier to adoption for research and diagnostic labs seeking to expand their multiplexing capabilities without major capital investment.

Risk Factors

Key risks include the challenge of driving adoption of a novel platform against entrenched competitors, the need for extensive third-party validation to build trust in the technology's claims, and the commercial execution risk of scaling manufacturing, sales, and support as a young company.

Competitive Landscape

Aplex Bio competes with established PCR vendors (Thermo Fisher, Bio-Rad, Qiagen) offering limited-plex qPCR/dPCR, and with NGS companies (Illumina, Thermo Fisher) offering high-plex sequencing. It also faces competition from other multiplexing technologies like Luminex's xMAP. Its differentiation lies in offering 100-plex capability with single-nucleotide specificity on standard PCR equipment, positioning it in a unique niche between these two major market segments.

More companies in Sweden →